Bookmark our Insights to Activate series exploring a range of timely topics, featuring impactful insights today that you can activate tomorrow.
The FDA approved it in 2012 for chronic weight management in adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity such as high blood pressure, type 2 diabetes, or high cholesterol
Prior authorization remains a hurdle that the vast majority of patients with coverage have to navigate Why this matters The demand for GLP-1 medications is surging, driven by the ongoing obesity epidemic in the United States, which affects 75% of American adults, and the mounting evidence of their benefits for weight management and beyond
Understanding Treatment Results Results from glutathione supplementation typically develop gradually
Investigated effect 2: Adipocyte lipid handling
Ipamorelin is a selective ghrelin receptor (GHS-R) agonist that stimulates GH release with minimal impact on cortisol or prolactin levels compared to earlier secretagogues[2][4]
